Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway

Fig. 4

Inhibition of miR-29b on the functions of HUVECs. a The expression of miR-29b in HUVECs was tested by qRT-PCR analyses after the transfection of miR-29b inhibitor. b The proliferation of HUVECs was tested after 48 h of incubation with 40 µg/ml of ExoC6-cer by MTT assay. c Migration assays were performed to explore the effects of ExoC6-cer on the migration abilities of HUVECs, which was photographed under a microscope at × 100 magnification (left-hand panels). The mean wound width was measured (right-hand panel). The images are representative of three independent experiments. d Tube formation of HUVECs treated differently was photographed under a microscope at × 100 magnification (left-hand panels). Mean tube length was quantified by image pro-plus software (right-hand panel). All the experiments were performed in triplicates. The images are representative of three independent experiments. (*P < 0.05)

Back to article page